{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:52:18Z","timestamp":1793371938440,"version":"4.5.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2632026ZD04"],"award-info":[{"award-number":["2632026ZD04"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22207125"],"award-info":[{"award-number":["22207125"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82574256"],"award-info":[{"award-number":["82574256"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejmech.2026.118963","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:10:12Z","timestamp":1778735412000},"page":"118963","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Induced proximity strategies for modulating immune checkpoints in cancer immunotherapy"],"prefix":"10.1016","volume":"315","author":[{"given":"Wenxin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2688-5015","authenticated-orcid":false,"given":"Tianyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6230","key":"10.1016\/j.ejmech.2026.118963_bib1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118963_bib2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40164-025-00627-6","article-title":"Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy","volume":"14","author":"Hu","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"issue":"5238","key":"10.1016\/j.ejmech.2026.118963_bib3","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ejmech.2026.118963_bib4","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.ejmech.2026.118963_bib5","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118963_bib6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1074-7613(04)00051-2","article-title":"Structural and functional analysis of the costimulatory receptor programmed death-1","volume":"20","author":"Zhang","year":"2004","journal-title":"Immunity"},{"issue":"19","key":"10.1016\/j.ejmech.2026.118963_bib7","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"12","key":"10.1016\/j.ejmech.2026.118963_bib8","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/j.str.2015.09.010","article-title":"Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1","volume":"23","author":"Zak","year":"2015","journal-title":"Structure"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118963_bib9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1084\/jem.20100619","article-title":"VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses","volume":"208","author":"Wang","year":"2011","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118963_bib10","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/0008-5472.CAN-13-1504","article-title":"VISTA is an immune checkpoint molecule for human T cells","volume":"74","author":"Lines","year":"2014","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118963_bib11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12943-024-02179-5","article-title":"Current trends in sensitizing immune checkpoint inhibitors for cancer treatment","volume":"23","author":"Wei","year":"2024","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.ejmech.2026.118963_bib12","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118963_bib13","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118963_bib14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"issue":"17","key":"10.1016\/j.ejmech.2026.118963_bib15","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1001\/jama.2017.14155","article-title":"Targeting immune checkpoints in cancer therapy","volume":"318","author":"Topalian","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118963_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.ejmech.2026.118963_bib17","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of Non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118963_bib18","first-page":"322","article-title":"The evolving landscape of immunotoxicity: charting mechanisms and future strategies for immune checkpoint inhibitor adverse events","volume":"1","author":"Lin","year":"2025","journal-title":"Med. Res."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118963_bib19","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","article-title":"Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -Extrinsic factors","volume":"44","author":"Pitt","year":"2016","journal-title":"Immunity"},{"issue":"21","key":"10.1016\/j.ejmech.2026.118963_bib20","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118963_bib21","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","article-title":"Advances in cancer immunotherapy: historical perspectives, current developments, and future directions","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol. Cancer"},{"issue":"6380","key":"10.1016\/j.ejmech.2026.118963_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/science.aao5902","article-title":"Chemically induced proximity in biology and medicine","volume":"359","author":"Stanton","year":"2018","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.ejmech.2026.118963_bib23","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1021\/acscentsci.3c00395","article-title":"Proximity-based modalities for biology and medicine","volume":"9","author":"Liu","year":"2023","journal-title":"ACS Cent. Sci."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118963_bib24","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118963_bib25","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.chembiol.2024.05.004","article-title":"Molecular glues and bifunctional compounds: therapeutic modalities based on induced proximity","volume":"31","author":"Schreiber","year":"2024","journal-title":"Cell Chem. Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118963_bib26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1152\/physrev.00012.2016","article-title":"Ubiquitination and the regulation of membrane proteins","volume":"97","author":"Foot","year":"2017","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118963_bib27","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1038\/s41467-023-42233-2","article-title":"Expanding PROTACtable genome universe of E3 ligases","volume":"14","author":"Liu","year":"2023","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118963_bib28","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118963_bib29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118963_bib30","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41587-025-02592-1","article-title":"Induced proximity at the cell surface","volume":"43","author":"Till","year":"2025","journal-title":"Nat. Biotechnol."},{"issue":"15","key":"10.1016\/j.ejmech.2026.118963_bib31","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1\u2013Cullin\u2013F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7930","key":"10.1016\/j.ejmech.2026.118963_bib32","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41586-022-05235-6","article-title":"Antibody targeting of E3 ubiquitin ligases for receptor degradation","volume":"610","author":"Marei","year":"2022","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.ejmech.2026.118963_bib33","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118963_bib34","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118963_bib35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"13","key":"10.1016\/j.ejmech.2026.118963_bib36","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1039\/D1CS00762A","article-title":"Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation","volume":"51","author":"Chen","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118963_bib37","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","article-title":"Targeted protein degradation: advances in drug discovery and clinical practice","volume":"9","author":"Zhong","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118963_bib38","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41568-025-00817-8","article-title":"Targeted protein degradation for cancer therapy","volume":"25","author":"Hinterndorfer","year":"2025","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118963_bib39","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1038\/s41467-021-25634-z","article-title":"The E3 ubiquitin ligase component, cereblon, is an evolutionarily conserved regulator of Wnt signaling","volume":"12","author":"Shen","year":"2021","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118963_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2022.107762","article-title":"Design, synthesis, and evaluation of PD-L1 degraders to enhance T cell killing activity against melanoma","volume":"34","author":"Liu","year":"2023","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118963_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112377","article-title":"Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1","volume":"199","author":"Cheng","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118963_bib42","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1021\/acscentsci.0c01306","article-title":"Carbon dots: a new type of carbon-based nanomaterial with wide applications","volume":"6","author":"Liu","year":"2020","journal-title":"ACS Cent. Sci."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118963_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202218128","article-title":"Targeted degradation of PD-L1 and activation of the STING pathway by carbon-dot-based PROTACs for cancer immunotherapy","volume":"62","author":"Su","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"issue":"16","key":"10.1016\/j.ejmech.2026.118963_bib44","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1021\/ja311795d","article-title":"A comprehensive mathematical model for three-body binding equilibria","volume":"135","author":"Douglass","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.118963_bib45","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pharmthera.2017.02.027","article-title":"Targeted protein degradation by PROTACs","volume":"174","author":"Neklesa","year":"2017","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118963_bib46","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118963_bib47","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrm2217","article-title":"Lysosomes: fusion and function","volume":"8","author":"Luzio","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.118963_bib48","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1146\/annurev.biochem.78.081307.110540","article-title":"Mechanisms of endocytosis","volume":"78","author":"Doherty","year":"2009","journal-title":"Annu. Rev. Biochem."},{"issue":"7820","key":"10.1016\/j.ejmech.2026.118963_bib49","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118963_bib50","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41467-022-28520-4","article-title":"The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system","volume":"13","author":"Ji","year":"2022","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118963_bib51","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nrm1050","article-title":"Mannose 6-phosphate receptors: new twists in the tale","volume":"4","author":"Ghosh","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118963_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41401-024-01364-y","article-title":"Targeted degradation of membrane and extracellular proteins with LYTACs","volume":"46","author":"Li","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"issue":"7413","key":"10.1016\/j.ejmech.2026.118963_bib53","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nature11308","article-title":"Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors","volume":"488","author":"Koo","year":"2012","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118963_bib54","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1021\/jacs.0c10008","article-title":"Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1","volume":"143","author":"Cotton","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.118963_bib55","article-title":"The membrane associated RING-CH proteins: a family of E3 ligases with diverse roles through the cell","volume":"2014","author":"Samji","year":"2014","journal-title":"Int. Sch. Res. Not."},{"key":"10.1016\/j.ejmech.2026.118963_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01751","article-title":"The membrane-associated MARCH E3 ligase family: emerging roles in immune regulation","volume":"10","author":"Lin","year":"2019","journal-title":"Front. Immunol."},{"issue":"42","key":"10.1016\/j.ejmech.2026.118963_bib57","doi-asserted-by":"crossref","first-page":"28497","DOI":"10.1074\/jbc.M805092200","article-title":"The single subunit transmembrane E3 Ligase gene related to anergy in lymphocytes (GRAIL) captures and then ubiquitinates transmembrane proteins across the cell membrane","volume":"283","author":"Lineberry","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118963_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.971162","article-title":"Negative regulation of receptor tyrosine kinases by ubiquitination: key roles of the Cbl family of E3 ubiquitin ligases","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Endocrinol."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118963_bib59","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/35067100","article-title":"Cbl: many adaptations to regulate protein tyrosine kinases","volume":"2","author":"Thien","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118963_bib60","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41587-022-01456-2","article-title":"Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins","volume":"41","author":"Pance","year":"2023","journal-title":"Nat. Biotechnol."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118963_bib61","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/protein\/9.7.617","article-title":"\u2018Knobs-into-holes\u2019 engineering of antibody CH3 domains for heavy chain heterodimerization","volume":"9","author":"Ridgway","year":"1996","journal-title":"Protein Eng."},{"issue":"48","key":"10.1016\/j.ejmech.2026.118963_bib62","doi-asserted-by":"crossref","first-page":"21831","DOI":"10.1021\/jacs.2c08367","article-title":"Bifunctional compounds as molecular degraders for integrin-facilitated targeted protein degradation","volume":"144","author":"Zheng","year":"2022","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118963_bib63","doi-asserted-by":"crossref","first-page":"7575","DOI":"10.1038\/s41467-025-62776-w","article-title":"Targeted degradation of cell surface proteins through endocytosis triggered by cell-penetrating peptide-small molecule conjugates","volume":"16","author":"He","year":"2025","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118963_bib64","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0165-6147(00)01447-4","article-title":"Cell-penetrating peptides","volume":"21","author":"Lindgren","year":"2000","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118963_bib65","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1038\/ncomms3787","article-title":"Structural and molecular basis of ZNRF3\/RNF43 transmembrane ubiquitin ligase inhibition by the Wnt agonist R-spondin","volume":"4","author":"Zebisch","year":"2013","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118963_bib66","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41467-024-55431-3","article-title":"Structural insights into the LGR4-RSPO2-ZNRF3 complexes regulating WNT\/\u03b2-catenin signaling","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"issue":"7706","key":"10.1016\/j.ejmech.2026.118963_bib67","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41586-018-0118-y","article-title":"RSPO2 inhibition of RNF43 and ZNRF3 governs limb development independently of LGR4\/5\/6","volume":"557","author":"Szenker-Ravi","year":"2018","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ejmech.2026.118963_bib68","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.chembiol.2023.05.010","article-title":"ROTACs leverage signaling-incompetent R-spondin for targeted protein degradation","volume":"30","author":"Sun","year":"2023","journal-title":"Cell Chem. Biol."},{"issue":"34","key":"10.1016\/j.ejmech.2026.118963_bib69","doi-asserted-by":"crossref","first-page":"19107","DOI":"10.1021\/jacs.3c07687","article-title":"Harnessing the lysosomal sorting signals of the cation-independent Mannose-6-Phosphate receptor for targeted degradation of membrane proteins","volume":"145","author":"Yu","year":"2023","journal-title":"J. Am. Chem. Soc."},{"issue":"42","key":"10.1016\/j.ejmech.2026.118963_bib70","doi-asserted-by":"crossref","first-page":"17652","DOI":"10.1039\/D4SC05093B","article-title":"Lysosome\u2013targeting chimeras containing an endocytic signaling motif trigger endocytosis and lysosomal degradation of cell-surface proteins","volume":"15","author":"Fang","year":"2024","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.118963_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116958","article-title":"Discovery of small molecules for autophagy-lysosome degradation of immune checkpoint proteins","volume":"280","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118963_bib72","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.molcel.2019.09.009","article-title":"AUTACs: Cargo-specific degraders using selective autophagy","volume":"76","author":"Takahashi","year":"2019","journal-title":"Mol. Cell"},{"issue":"5","key":"10.1016\/j.ejmech.2026.118963_bib73","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1021\/acs.jmedchem.1c01682","article-title":"Discovery of small-molecule inhibitors of the PD-1\/PD-L1 axis that promote PD-L1 internalization and degradation","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118963_bib74","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.apsb.2025.02.037","article-title":"GPC3-mediated lysosome-targeting chimeras (GLTACs) for targeted degradation of membrane proteins","volume":"15","author":"Fang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118963_bib75","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.trecan.2023.11.001","article-title":"Targeting HER2 heterogeneity in breast and gastrointestinal cancers","volume":"10","author":"Valenza","year":"2024","journal-title":"Trends Cancer"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118963_bib76","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202410778","article-title":"Precise HER2 protein degradation via peptide-conjugated photodynamic therapy for enhanced breast cancer immunotherapy","volume":"12","author":"Guo","year":"2025","journal-title":"Adv. Sci."},{"issue":"41","key":"10.1016\/j.ejmech.2026.118963_bib77","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202511467","article-title":"HerTACs enable tumor-selective lysosomal degradation of membrane and extracellular proteins via HER2 trafficking","volume":"64","author":"He","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"issue":"7873","key":"10.1016\/j.ejmech.2026.118963_bib78","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.ejmech.2026.118963_bib79","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.addr.2004.01.010","article-title":"Folate receptor endocytosis and trafficking","volume":"56","author":"Sabharanjak","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118963_bib80","doi-asserted-by":"crossref","first-page":"8695","DOI":"10.1038\/s41467-024-52685-9","article-title":"Development of folate receptor targeting chimeras for cancer selective degradation of extracellular proteins","volume":"15","author":"Zhou","year":"2024","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118963_bib81","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","article-title":"Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups","volume":"20","author":"Andrews","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2026.118963_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104258","article-title":"Understanding and overcoming the resistance of cancer to PD-1\/PD-L1 blockade","volume":"145","author":"Shergold","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118963_bib83","doi-asserted-by":"crossref","first-page":"8804","DOI":"10.1038\/s41467-025-63882-5","article-title":"Dual membrane receptor degradation via folate receptor targeting chimera","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.ejmech.2026.118963_bib84","doi-asserted-by":"crossref","first-page":"15807","DOI":"10.1021\/acs.jmedchem.4c01449","article-title":"Peptide-mediated small molecule lysosome-targeting chimeras for targeted degradation of membrane and intracellular proteins","volume":"67","author":"Chen","year":"2024","journal-title":"J. Med. Chem."},{"issue":"D1","key":"10.1016\/j.ejmech.2026.118963_bib85","doi-asserted-by":"crossref","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","article-title":"Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics","volume":"53","author":"Jiang","year":"2025","journal-title":"Nucleic Acids Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T19:46:48Z","timestamp":1783194408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426004083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":85,"alternative-id":["S0223523426004083"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118963","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Induced proximity strategies for modulating immune checkpoints in cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118963","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118963"}}